

Fig. 1



Fig. 1


A
200
20
9
12
13
18a
19
16
14
18b
15
6
17
B
200
C
20
21
22
23
7
9
6
16
18b
17

Fig. 2


A
200
20
10
8
11
9
12
18a
13
19
16
6
14
18b
15
17
B
200
C
20
10
7
22
21
23
8
7
9
11
6
16
18b
17

Fig. 3

A



B



Fig. 4

A


25
500
26
50
27
28
36a
29
32
6
30
36b
31
33
34
35

B


39
40
48
49
42
37
38
25
50
26
41
7
27
47
32
6
46
51
45
36b
33
44
34
43
35

Fig. 5

C


500
50
28
26
27
32
6
36b
33
34
35
39
40
48
49
42
37
38
41
47
41
46
51
45
44
43

Fig. 5

D


39
40
500
48
49
42
25
50
37
38
26
27
47
41
32
6
46
51
45
36b
33
44
34
43
35

Fig. 5



Fig. 6

C



D



Fig. 6

A



B



Fig. 7

C



D



Fig. 7



Fig. 8



Fig. 9



Fig. 10


A
Caco-2 Acridine Orange
EA.hy926 Acridine Orange
IMASMC Acridine Orange
B
Caco-2 HEA-FITC/DAPI
EA.hy926 CD31-FITC/DAPI
IMASMC αSMA/DAPI
C
D
Caco-2
EA.hy926
p53 (-CT)
cTop m
cTop m up
cTop m down
cTop n
cTop m membrane
cTop m membrane
cTop n membrane
cTop n membrane

Fig. 11



Fig. 12



Fig. 13


C
274
288
284
275
276
273
280
269
200
272
274
278
279
271
270a
287
286
207
270b

Fig. 13